First, patients in the low SLC25A21 expression group had shorter OS than those in the high SLC25A21 expression group (p value = 0.006, Figure 3A), which indicated that a low SLC25A21 expression level was associated with an unfavourable prognosis in patients with AML. This evidence concerns the gene SLC25A21 and acute myeloid leukemia.